AHCPR/RAND depression cost-effectiveness study in prepaid primary care settings: five years, $7.2 mil. in funds.
AHCPR COST-EFFECTIVENESS STUDY OF DEPRESSION IN PREPAID PRIMARY CARE settings will take place over a period of five years supported by a $7.2 mil. AHCPR grant to the RAND Corp. research institute. HHS' Agency for Health Care Policy & Research announced the program June 1, noting that it chose prepaid managed primary care because it is the "fastest growing segment of the health care industry."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth